Finding the straw that breaks the cancer's back?

Authors

DOI:

https://doi.org/10.25250/thescbr.brk687

Keywords:

Therapy Resistance, Pancreatic Cancer, Cell Death, NOXA, RUNX1

Abstract

One of the major challenges in cancer therapy is the recurrent emergence of resistance. In pancreatic cancer, we uncovered one such resistance mechanism. Inhibiting a protein which is highly expressed in a therapy-resistant subtype of pancreatic cancer could pave the way for new therapies and improve survival of patients.

Author Biographies

Hazal Köse, Freie Universität Berlin and Humboldt-Universität zu Berlin

PhD student

Matthias Wirth, Freie Universität Berlin and Humboldt-Universität zu Berlin

Principal Investigator

Original article reference

Doffo, J., Bamopoulos, S. A., Köse, H., Orben, F., Zang, C., Pons, M., den Dekker, A. T., Brouwer, R. W. W., Baluapuri, A., Habringer, S., Reichert, M., Illendula, A., Krämer, O. H., Schick, M., Wolf, E., van IJcken, W. F. J., Esposito, I., Keller, U., Schneider, G., & Wirth, M. (2022). NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Proceedings of the National Academy of Sciences, 119(9). https://doi.org/10.1073/pnas.2105691119

Downloads

  • URL

Published

2023-03-10

Issue

Vol. 9 No. 1 (2023): TheScienceBreaker

Section

Health & Physiology

License

Some rights reserved 2023 Hazal Köse, Matthias Wirth

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.